Pharmaceutical Development. Stability studies for drug product, 10 mg capsules and placebo, are ongoing at Triangle. This study will continue at Triangle in support of study FTCB-204 and will not be transferred to Bukwang. Results will be provided to Bukwang as they become available. • A campaign to produce additional CTM at Patheon in August has been cancelled.
Appears in 2 contracts
Sources: License Agreement (Pharmasset Inc), License Agreement (Pharmasset Inc)